Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaFRA:O6PA 58 PEG Ratio is 0.00 as of Jul. 24, 2026. GuruFocus rates FRA:O6PA with a GF Score™ of 58/100. The stock has 10 warning signs investors should review. Among 350 Drug Manufacturers companies, Orchid Pharma ranks worse than 98.57% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Orchid Pharma's PEG Ratio or its related term are showing as below:
FRA:O6PA'
s PEG Ratio Range Over the Past 10 Years
Min: 0.94 Med: 4.3 Max: 20.98
Current: 73.72
During the past 13 years, Orchid Pharma's highest PEG Ratio was 20.98. The lowest was 0.94. And the median was 4.30.
FRA:O6PA's PEG Ratio is ranked worse than 98.57% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs FRA:O6PA: 73.72
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Orchid Pharma (FRA:O6PA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Orchid Pharma PEG Ratio Related Terms
Orchid Pharma PEG Ratio Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Orchid Pharma (FRA:O6PA) has a PEG Ratio of 0.00 as of Jul. 24, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Orchid Pharma and its competitors. Over the past decade, Orchid Pharma's PEG Ratio has ranged from 0.94 to 20.98. According to the industry distribution chart, Orchid Pharma ranks #345 out of 350 companies in the Drug Manufacturers industry, placing it in the top 98.6%.
Is Orchid Pharma's PEG Ratio too high?
Orchid Pharma's current PEG Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 20.98. Based on the distribution chart, Orchid Pharma ranks #345 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orchid Pharma has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #345 out of 350 companies for PEG Ratio. This places Orchid Pharma in the lower half of its industry. The industry median PEG Ratio is 1.72. Historically, Orchid Pharma's own PEG Ratio has ranged from 0.94 to 20.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (FRA:O6PA) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Orchid Pharma's overall GF Score™ is 58/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Orchid Pharma (FRA:O6PA), the current PEG Ratio is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O6PA has been successfully added to your 
